ID   U266-PSR
AC   CVCL_E5J9
SY   U266PSR
RX   DOI=10.1182/blood.V124.21.2084.2084;
CC   Population: Caucasian.
CC   Characteristics: Resistant to 15 nM of bortezomib (DOI=10.1182/blood.V124.21.2084.2084).
CC   Characteristics: Produces IgE lambda (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI_52717; Bortezomib (Velcade).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0566 ! U266B1
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   DOI=10.1182/blood.V124.21.2084.2084;
RA   Turner J.G., Dawson J.L., Grant S., Shain K.H., Dai Y., Cubitt C.L.,
RA   Baz R.C., Nishihori T., Kauffman M.G., Shacham S., Sullivan D.M.;
RT   "Melphalan and XPO1 inhibitor combination therapy for the treatment of
RT   multiple myeloma.";
RL   Blood 124 Suppl. 1:2084-2084(2014).
//